Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110932 | 0.84 | KDM4E (0.46) | KDM4EGLAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29413053 | 0.84 | KDM4E (0.46) | KDM4EGLAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2154955 | 0.84 | KDM4E (0.46) | KDM4EGLAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28051617 | 0.80 | KDM4E (0.60) | KDM4EGLAHSD17B10GABRPGABRD | |
| SCHEMBL19705808 | 0.80 | KDM4E (0.41) | KDM4EGLAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL759268 | 0.79 | KDM4E (0.47) | KDM4EGLAHSD17B10MAPTNOTUM | |
| SCHEMBL634151 | 0.79 | KDM4E (0.42) | KDM4EGLAHSD17B10MAPTPOLB | |
| SCHEMBL24399523 | 0.79 | AKR1C3 (0.50) | KDM4EGLAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL5424439 | 0.79 | KDM4E (0.70) | KDM4EHSD17B10GABRPGABRDGABRA1 | |
| SCHEMBL1553215 | 0.79 | KDM4E (0.70) | KDM4EAKR1C2AKR1C1HSD17B10GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406035-A | Preparation method of cyantraniliprole metabolite IN-PLT97 | 山东亿盛实业股份有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-104031026-A | O-formylamino benzamide derivatives containing N-cyano sulfone(sulfur)imine, preparation method thereof and uses thereof | UNIV NANKAI | 2014-09-10 | — | — | CN | claimed |
| EP-1903030-B1 | Method for catalytic manufacture of aromatic or heteroaromatic nitriles | SALTIGO GMBH (DE) | 2014-06-04 | — | — | EP | claimed |
| CN-103172613-A | O-formamido benzamide derivative containing N-cyano sulfone (sulfur) imine and preparation method and application thereof | UNIV NANKAI | 2013-06-26 | — | — | CN | claimed |
| US-7592452-B2 | Process for catalytically preparing aromatic or heteroaromatic nitriles | SALTIGOGMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20090062541-A1 | Process for catalytically preparing aromatic or heteroaromatic nitriles | SALTIGO GMBH (DE) | 2009-03-05 | — | — | US | claimed |
| EP-1903030-A1 | Method for catalytic manufacture of aromatic or heteroaromatic nitriles | Saltigo GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025067468-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112566906-B | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240327395-A1 | A PROCESS FOR PREPARING BENZOXAZINONE COMPOUNDS | TAGROS CHEMICALS INDIA PVT LTD (IN) | 2024-10-03 | — | — | US | disclosed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-0938471-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
| CN-1240429-A | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0938471-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929097-A | INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1998016503-A2 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062541-A1 | Process for catalytically preparing aromatic or heteroaromatic nitriles | AHR, PAH, AOC3 | KDM4E 612/4885GLA 3384/4885AKR1C3 49/4885 |
| US-20240327395-A1 | A PROCESS FOR PREPARING BENZOXAZINONE COMPOUNDS | XDH, PDHX, CYP11B1 | KDM4E 1398/4885GLA 2449/4885AKR1C3 396/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | KDM4E 3553/4885GLA 1819/4885AKR1C3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.